Skip to main content

Table 3 Details of all complications in landiolol and placebo groups

From: Landiolol hydrochloride for prevention of atrial fibrillation during esophagectomy: a randomized controlled trial

 

Clavien grade II complications

Clavien grade ≥ III (severe) complications

Type of complication

Landiolol (n = 28)

Placebo (n = 28)

Landiolol (n = 28)

Placebo (n = 28)

All

4 (14.2)

7 (25.0)

7 (25.0)

7 (25.0)

Mortality

0 (0.0)

0 (0.0)

1 (3.6)

0 (0.0)

Gastric tube necrosis

1 (3.6)

0 (0.0)

2 (7.1)

0 (0.0)

Anastomotic stenosis

0 (0.0)

0 (0.0)

1 (3.6)

0 (0.0)

Anastomotic leakage

1 (3.6)

0 (0.0)

5 (17.9)

3 (10.7)

Pneumonia

0 (0.0)

3 (10.7)

0 (0.0)

0 (0.0)

Vocal cord paralysis

2 (7.1)

3 (10.7)

0 (0.0)

0 (0.0)

Supraventricular tachycardia

0 (0.0)

1 (3.6)

0 (0.0)

0 (0.0)

Sepsis

0 (0.0)

1 (3.6)

0 (0.0)

0 (0.0)

Pleural effusion

0 (0.0)

1 (3.6)

0 (0.0)

4 (14.3)

Intestinal ischemia

0 (0.0)

0 (0.0)

1 (3.6)

0 (0.0)

Intrathoracic bleeding

0 (0.0)

0 (0.0)

0 (0.0)

1 (3.6)

  1. Data are expressed as number (%)